On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US.
By
Clark Herman
| Published: August 1, 2013
On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US. These priorities signal public and private policymakers alike to improve the way patients take their medication.
In 2009, NEHI published research which found that people with poor medication adherence, either by not taking their medication accordingly or not at all, cost the US health care system $290 billion annually. In addition to this research, the Congressional Budget Office published its own study describing the beneficial impact of adherence to therapy; with a projected 5% increase from exposure of Medicare to cover drugs would lead to a 1% decrease in the programs medical and hospital spending.
NEHI’s new report, which resulted from a series of roundtables on adherence in 2012, focuses on the following six points in developing a comprehensive, system-wide solution:
For more information, visit NEHI’s website: http://www.nehi.net
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.